Azithromycin

83905-01-5

C38H72N2O12

DMSO : >= 100 mg/mL (133.51 mM); H2O : < 0.1 mg/mL (insoluble)

Anti-infection; Autophagy

Azithromycin is a macrolide antibiotic useful for the treatment of a number of bacterial infections. In Vitro: Azithromycin (2 uM) augments rhinovirus-induced IFNbeta expression in primary bronchial epithelial cells from asthmatics, which is associated with over-expression of RIG-I like receptors and repression of viral replication. Knockdown of MDA5, but not knockdown of RIG-I, diminishes azithromycin (2 uM)-enhanced viral-induced IFNbeta expression in asthmatic primary bronchial epithelial cells^[1]. Azithromycin specifically reduces MMP-9 mRNA and protein levels without affecting NF-kappaB in endotoxin-challenged monocytic THP-1 cells^[2]. In Vivo: Azithromycin (50 mg/kg) has no effect on bronchoalveolar lavage inflammatory parameters and LDH levels in a mouse model of asthma exacerbation. Azithromycin induces neither general inflammatory parameters nor LDH release in a mouse model of asthma exacerbation, and augments expression of interferon-stimulated genes and the pattern recognition receptor MDA5 but not RIG-I in exacerbating mice^[1].